Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Patent Board Orders More Data From Novartis In Glivec Appeal

This article was originally published in PharmAsia News

Executive Summary

Novartis, the Swiss drug maker, has been instructed to provide more information if it expects to win its appeal of a ruling against a patent for its Glivec (imatinib) blood-cancer drug. The Intellectual Property Appellate Board told Novartis to submit documents supporting its claim that a newer version of the drug enhanced its efficacy. Novartis is appealing a previous ruling rejecting its claim against generics proposed by Cipla, Natco Pharma and Ranbaxy Laboratories, in addition to the Cancer Patients' Aid Association. (Click here for more

You may also be interested in...

Novartis Wants Tighter Grip Over Its Indian Ops; Announces Open Offer To Up Stake To 90%

MUMBAI - Swiss-headquartered Novartis announced a tender offer to buy an additional stake of up to 39 percent in its majority-owned Indian subsidiary Novartis India. The Swiss drug maker, which markets popular pain killer Voveran (diclofenac) in India among several other products, would raise its stake in the subsidiary to nearly 90 percent if the open offer for the shares passes successfully

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

International Harmonization: Not Just For Audits Anymore

The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts